GOQii, Acrannolife Genomics launch program to improve post-transplant care in India

Mumbai: GOQii, a smart preventive healthcare company, has partnered with Acrannolife Genomics to introduce the GrafCare Program, aimed at improving post-transplant care for organ recipients in India.

The program combines genomic diagnostics, artificial intelligence, and health monitoring to help detect complications early and support long-term recovery.

Acrannolife’s Trunome test, a non-invasive blood test, helps identify early signs of organ rejection or infection. GOQii’s Smart Vital Device tracks vital health parameters such as heart rate, blood pressure, and oxygen levels, providing real-time data for proactive care. Patients also receive guidance from nutritionists and counselors to manage their health and recovery.

“This is more than a health program; it’s a lifeline for transplant recipients,” said Vishal Gondal, Founder & CEO, GOQii.
"The GrafCare Program, powered by our US-patented Trunome test, offers early and accurate detection of organ rejection, giving patients the best chance to protect their graft," said Agragesh Ramani, Co-founder, Acrannolife Genomics.

The program offers financial support through interest-free loans, discounts on immunosuppressants, and free diagnostic tests. With thousands of transplants performed annually in India, the initiative focuses on using AI and genomics to help patients and doctors address potential health risks before complications arise. Future plans include expanding the program to other regions with high transplant rates.